Related Experiment Video
Updated: Jan 9, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like
Raweekarn Itsathitpaisarn1, Nattavong Suksawad2, Watsapol Wongwikrom2
1Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Abstract:
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become important in the treatment of diabetic kidney disease (DKD). Despite their reno-protective effect, kidney injury from GLP-1 RAs has been rarely reported. The reported kidney injuries varied from mild symptoms to dialysis at presentation and occurred 2 days to 2 years after drug initiation. We report a case of a patient with DKD who developed an episode of interstitial nephritis after dulaglutide administration. CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan. Sodium-glucose cotransporter-2 inhibitor was not prescribed in this case due to her frequent urinary tract infections. Serum creatinine at 2-month follow-up increased and then doubled despite reduction in the azilsartan dose. Potentially nephrotoxic medications were discontinued and no other possible causes of kidney injury, including volume depletion, were presented. Kidney biopsy revealed active interstitial nephritis and diabetic nephropathy without accumulation of immune complex. After discontinuing dulaglutide, there was an almost complete recovery of kidney function without steroid therapy. Azilsartan and chlorthalidone could then be successfully rechallenged. CONCLUSIONS Despite the established renoprotective effect of GLP-1 RAs, acute-to-chronic tubulointerstitial nephritis occasionally occurs, requiring vigilant monitoring after drug initiation or titration. Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate DKD progression in certain patients. Treatment includes drug discontinuation and steroid therapy in non-responders.
Insights
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can rarely cause interstitial nephritis in diabetic kidney disease (DKD) patients. Discontinuation of the drug led to kidney function recovery, highlighting the need for monitoring.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are crucial in managing diabetic kidney disease (DKD).
- While generally renoprotective, rare instances of kidney injury associated with GLP-1 RAs have been documented, presenting with varied severity and onset times.
Purpose of the Study:
- To report a case of interstitial nephritis in a patient with DKD following dulaglutide administration.
- To emphasize the importance of monitoring for potential adverse renal events associated with GLP-1 RA therapy.
Main Methods:
- A case report of a 63-year-old woman with stage 3b DKD is presented.
- The patient developed elevated creatinine levels after initiating dulaglutide, with kidney biopsy confirming interstitial nephritis.
- Nephrotoxic medications were ceased, and other causes of kidney injury were excluded.
Main Results:
- The patient experienced a doubling of serum creatinine after dulaglutide initiation.
- Kidney biopsy revealed active interstitial nephritis and diabetic nephropathy.
- Discontinuation of dulaglutide resulted in near-complete recovery of kidney function without the need for steroid therapy.
Conclusions:
- Acute-to-chronic tubulointerstitial nephritis is a rare but possible adverse effect of GLP-1 RAs in DKD patients.
- Vigilant monitoring is essential during GLP-1 RA initiation or dose adjustment.
- GLP-1 RAs remain valuable for DKD management, with treatment involving drug cessation and potentially steroids for non-responders.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Pyelonephritis I: Introduction

